Testing of 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) in mouse L1210 leukemia and 37 sarcoma
Abstract:
The antimetabolite 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) has been investigated in an attempt to elucidate its effects on survival time of DBA/2 and B6D2F1 mice with L1210 leukemia and of outbred albino mice with 37 sarcoma. A significant increase in survival time was observed in mice with 37 sarcoma and slight effects were observed in mice with L1210 leukemia when treated with 3 x 12.5 or 3 x 25 mg/kg of 3-oxauracil. No toxic side effects were observed when large therapeutic doses of the drug were given.
Insights
The antimetabolite 3-oxauracil significantly increased survival time in mice with 37 sarcoma and showed slight effects against L1210 leukemia. This compound demonstrated no toxicity, even at high therapeutic doses.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Antimetabolites are a class of drugs that interfere with essential metabolic processes.
- 3-oxauracil is an antimetabolite investigated for its potential anticancer properties.
Purpose of the Study:
- To evaluate the efficacy of 3-oxauracil in extending survival time in mouse models of sarcoma and leukemia.
- To assess the toxic side effects of 3-oxauracil at therapeutic doses.
Main Methods:
- Treatment of DBA/2 and B6D2F1 mice with L1210 leukemia and outbred albino mice with 37 sarcoma.
- Administration of 3-oxauracil at doses of 3 x 12.5 mg/kg and 3 x 25 mg/kg.
- Monitoring and comparison of survival times between treated and control groups.
Main Results:
- A significant increase in survival time was observed in mice bearing 37 sarcoma.
- Slight improvements in survival time were noted in mice with L1210 leukemia.
- No toxic side effects were detected, even with high doses of 3-oxauracil.
Conclusions:
- 3-oxauracil shows promising anticancer activity, particularly against 37 sarcoma.
- The compound is well-tolerated, suggesting potential for further clinical development.
- Further research is warranted to explore the therapeutic potential of 3-oxauracil in cancer treatment.
